Over 1,000 Chemotherapy Protocols And Counting

A Phase II, Randomized, Open-label, multicenter trial Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer Avelumab (n=65) vs

20 May

Follicular Lymphoma

New Reference: SubQ Rituximab for Follicular Lymphoma

Randomized, open-label phase 3 trial (LYSA) Previously untreated low-burden Follicular lymphoma SOC (n=102) vs. Rituximab sc (n=100)

20 May

Chronic Lymphocytic Leukemia

New Reference: Ibrutinib and Rituximab for CLL

Phase III, randomized,controlled, multicenter, open-label trial (FLAIR) Treatment naive CLL–small lymphocytic lymphoma (SLL) İbrutinib + Rituximab (n=386) vs. FCR (n=385)

20 Sep

Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

Randomized, open-label, international, multicenter phase III study Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib Ripretinib 150 mg (n = 2

14 Apr

Bladder Cancer

New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer

Multicenter, open-label, phase 1/2 trial Cisplatin ineligible local advanced/metastatic urothelial carcinoma Enfortumab vedotin +pembrolizumab q21 (n=45)

20 May

Colorectal Cancer

New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer

Phase III, randomized, open-label trial (SUNLIGHT) Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer

14 Apr

Uterine Cancer

New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer

Phase III, randomized, double-blind, placebo-controlled Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma Pembrolizuma

15 Mar

Breast Cancer

New Drug: Elacestrant for ER+ Breast Cancer

International, multicenter, randomized, open-label, phase III (EMERALD) ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretre

16 Jul

GastroEsophageal Cancer

New Protocol: Perioperative FLOT with Trastuzumab and Pertuzumab for her2-Positive Gastroesophageal Cancer

Multicenter, randomized phase II/III trial HER 2–positive, >= clinical tumor 2 or clinical nodal–positive resectable EGA Four pre and postoperative cycles of either FLOT alone

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries